Longitudinal Effect of Guselkumab on Biomarkers of Inflammation and Cardiovascular Risk in Bionaive Patients with Active Psoriatic Arthritis and High Systemic Inflammatory Burden: Post-hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-Controlled Study

被引：0

作者：

Kavanaugh, Arthur ^{[1
]}

Soriano, Enrique ^{[2
,3
]}

Dutz, Jan ^{[4
]}

Selmi, Carlo ^{[5
]}

Rampakakis, Emmanouil ^{[6
]}

Shiff, Natalie ^{[7
]}

Nantel, Francois ^{[8
]}

Lavie, Frederic ^{[9
]}

Coates, Laura ^{[10
]}

机构：

[1] Univ Calif San Diego, Div Rheumatol Allergy & Immunol, La Jolla, CA USA

[2] Hosp Italiano Buenos Aires, Internal Med Serv, Rheumatol Sect, Buenos Aires, DF, Argentina

[3] Univ Inst Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina

[4] Vancouver Gen Hosp, Dept Dermatol & Skin Sci, Vancouver, BC, Canada

[5] Humanitas Univ, Humanitas Res Hosp Internal Med, Rheumatol & Clin Immunol, Rozzano, Italy

[6] McGill Univ, JSS Med Res, Sci Affairs, Dept Pediat, Montreal, PQ, Canada

[7] Univ Saskatchewan, Immunol, Janssen Sci Affairs LLC Adjunct, Horsham, PA USA

[8] Nantel Medsci Consult, Montreal, PQ, Canada

[9] Janssen Pharmaceut Companies Johnson & Johnson, Paris, France

[10] Univ Oxford, Oxford, England

来源：

ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷

关键词：

BIOLOGIC-NAIVE;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2238

引用

页码：4421 / 4424

页数：4

共 50 条

[21] Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)
Hideto Kameda
Kohei Hagimori
Yoji Morisaki
Thorsten Holzkämper
Ayako Konomi
Hiroaki Dobashi
Rheumatology and Therapy, 2023, 10 : 1683 - 1703
[22] Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Ritchlin, Christopher
Mease, Philip J.
Boehncke, Wolf-Henning
Tesser, John
Chakravarty, Soumya
Rampakakis, Emmanouil
Shawi, May
Schiopu, Elena
Merola, Joseph
McInnes, Iain B.
Deodhar, Atul
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4178 - 4182
[23] EFFICACY AND SAFETY OF GUSELKUMAB IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE AXIAL PSORIATIC ARTHRITIS: STUDY DESIGN OF A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Gladman, D. D.
Mease, P. J.
Bird, P.
Soriano, E.
Chakravarty, S. D.
Shawi, M.
Xu, S.
Quinn, S.
Gong, C.
Leibowitz, E.
Tam, L. S.
Helliwell, P.
Kavanaugh, A.
Deodhar, A.
Ostergaard, M.
Baraliakos, X.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1574 - 1575
[24] Efficacy and Safety Results of Guselkumab in Patients with Active Psoriatic Arthritis over 56 Weeks from a Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
Deodhar, Atul A.
Gottlieb, Alice B.
Boehncke, Wolf-Henning
Dong, Bin
Wang, Yuhua
Zhuang, Yanli
Barchuk, William
Xu, Xie L.
Hsia, Elizabeth
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[25] Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials
Shapiro, Robert E.
Hochstetler, Helen M.
Dennehy, Ellen B.
Khanna, Rashna
Doty, Erin Gautier
Berg, Paul H.
Starling, Amaal J.
JOURNAL OF HEADACHE AND PAIN, 2019, 20 (01):
[26] Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials
Robert E. Shapiro
Helen M. Hochstetler
Ellen B. Dennehy
Rashna Khanna
Erin Gautier Doty
Paul H. Berg
Amaal J. Starling
The Journal of Headache and Pain, 2019, 20
[27] Safety of efalizumab in patients with psoriatic arthritis: Results of a phase II, randomized, double-blind, placebo-controlled study
Papp, K
Mease, P
Garovoy, M
Zhang, D
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P156 - P156
[28] Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
Mease, Philip J.
Rahman, Proton
Gottlieb, Alice B.
Kollmeier, Alexa P.
Hsia, Elizabeth C.
Xu, Xie L.
Sheng, Shihong
Agarwal, Prasheen
Zhou, Bei
Zhuang, Yanli
van der Heijde, Desiree
McInnes, Iain B.
LANCET, 2020, 395 (10230): : 1126 - 1136
[29] Impact of Psoriatic Arthritis Manifestations on Perception of Pain Improvement: Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies with Guselkumab
Nash, Peter
McInnes, Iain
Ritchlin, Christopher T.
Tam, Lai-Shan
Soriano, Enrique
Starr, Michael
Rampakakis, Emmanouil
Lavie, Frederic
Shawi, May
Baraliakos, Xenofon
Mease, Philip J.
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2785 - 2787
[30] Impact of Galcanezumab on Total Pain Burden: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Episodic Cluster Headache
Andrews, J. Scott
Kudrow, David
Rettiganti, Mallikarjuna
Oakes, Tina
Bardos, Jennifer N.
Wenzel, Richard
Kuruppu, Dulanji K.
Gaul, Charly
Martinez, James M.
JOURNAL OF PAIN RESEARCH, 2021, 14 : 2059 - 2070

← 1 2 3 4 5 →